Showing 111-120 of 598 results for "".
Sensus Healthcare: What's Next
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-next/19947/Along with other healthcare companies, Sensus faced challenges in 2020 as the COVID-19 pandemic emerged. But CEO Joe Sardano says the company is poised for success in 2021 and beyond. He discusses efforts to optimize physician reimbursement and strategies to expand access for patients.Sensus Healthcare: What's New
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-new/19946/Adding to its flagship SRT-100 device for superficial radiation therapy, Sensus has launched the Sculptura® Radiotherapy Oncology System and is poised to bring new aesthetic devices to market. Sensus CEO Joe Sardano says that as it grows, the company remains focused on relationships with its clientsFDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.Cosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.Part 3: New Developments in Biologics
https://practicaldermatology.com/topics/psoriasis/part-3-new-developments-in-biologics/18965/In this edition of Derm Insider, host Neal Bhatia, MD tackles the evolving systemic treatment landscape for psoriasis with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD. In Part III, they discuss new developments in biologic therapy.Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentTargeting Senescent Cells
https://practicaldermatology.com/videos/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesThree's the Charm
https://practicaldermatology.com/topics/practice-management/threes-the-charm/20585/Expert injectors discuss the promise and perils of Botox Cosmetic's third nod.The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,SCALE 2024: Listen as Dr. Joel Cohen and Dr. Suneel Chilukuri on Microwave Therapy
https://practicaldermatology.com/error/404/Suneel Chilukuri, MD, discusses the various applications of microwave therapy, including non-melanoma skin cancer, with Joel Cohen, MD, at Music City SCALE.